

1 **Genetic profile and functional proteomics of anal squamous cell carcinoma: proposal**  
2 **for a molecular classification**

3 Lucía Trilla-Fuertes<sup>1#</sup>, Ismael Ghanem<sup>2#</sup>, Angelo Gámez-Pozo<sup>3</sup>, Joan Maurel<sup>4</sup>, Laura G-  
4 PASTRIÁN<sup>5,6</sup>, Marta Mendiola<sup>6,7</sup>, Cristina Peña<sup>5</sup>, Rocío López-Vacas<sup>3</sup>, Guillermo Prado-Vázquez<sup>1</sup>,  
5 Elena López-Camacho<sup>3</sup>, Andrea Zapater-Moros<sup>3</sup>, Victoria Heredia<sup>7,8</sup>, Miriam Cuatrecasas<sup>9</sup>, Pilar  
6 García-Alfonso<sup>10</sup>, Jaume Capdevila<sup>11</sup>, Carles Conill<sup>12</sup>, Rocío García-Carbonero<sup>13</sup>, Ricardo Ramos-  
7 Ruiz<sup>14</sup>, Claudia Fortes<sup>15</sup>, Carlos Llorens<sup>16</sup>, Paolo Nanni<sup>15</sup>, Juan Ángel Fresno Vara<sup>3,7</sup>, Jaime  
8 Feliu<sup>2,7,17\*</sup>

9 <sup>1</sup> Biomedica Molecular Medicine SL, C/ Faraday 7, 28049, Madrid, Spain.

10 <sup>2</sup> Medical Oncology Department, Hospital Universitario La Paz, Paseo de la Castellana 261,  
11 28046, Madrid, Spain

12 <sup>3</sup> Molecular Oncology & Pathology Lab, Institute of Medical and Molecular Genetics-INGEMM,  
13 Hospital Universitario La Paz -IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain.

14 <sup>4</sup> Medical Oncology Department, Hospital Clinic of Barcelona, Translational Genomics and  
15 Targeted Therapeutics in Solid Tumors Group, IDIBAPS, University of Barcelona, Carrer de  
16 Villarroel 170, 08036, Barcelona, Spain

17 <sup>5</sup> Pathology Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046,  
18 Madrid, Spain

19 <sup>6</sup> Molecular Pathology and Therapeutic Targets Group, Hospital Universitario La Paz-IdiPAZ,  
20 Paseo de la Castellana 261, 28046, Madrid, Spain.

21 <sup>7</sup> Biomedical Research Networking Center on Oncology-CIBERONC, ISCIII, Av. Monforte de  
22 Lemos 5, 28029, Madrid, Spain

23 <sup>8</sup> Translational Oncology Lab, Hospital Universitario La Paz -IdiPAZ, Paseo de la Castellana 261,  
24 28046, Madrid, Spain.

25 <sup>9</sup> Pathology Department, Hospital Clínic Universitari de Barcelona, Carrer de Villarroel 170,  
26 08036, Barcelona, Spain

27 <sup>10</sup> Medical Oncology Department, Hospital General Universitario Gregorio Marañón, /Dr.  
28 Esquerdo 46, 28007, Madrid, Spain.

29 <sup>11</sup> Medical Oncology Service, Vall Hebron University Hospital. Vall Hebron Institute of Oncology  
30 (VHIO), Paseigg de la Vall d'Hebron 119, 08035, Barcelona, Spain.

31 <sup>12</sup> Radiotherapy Oncology Department, Hospital Clínic Universitari de Barcelona, Carrer de  
32 Villarroel 170, 08036, Barcelona, Spain.

33 <sup>13</sup> Medical Oncology Service, Hospital Universitario 12 de Octubre, Av. de Córdoba s/n, 28041,  
34 Madrid, Spain.

35 <sup>14</sup> Genomics Unit Cantoblanco, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid,  
36 Spain.

37 <sup>15</sup> Functional Genomics Center Zurich, University of Zurich/ETH Zurich, Winterthurerstrasse  
38 190, CH-8057, Zurich, Switzerland

39 <sup>16</sup> Biotechvana SL, Parque Científico de Madrid, C/ Faraday 7, 28049, Madrid, Spain.

40 <sup>17</sup> Cátedra UAM-Amgen, Universidad Autónoma de Madrid, Ciudad Universitaria de  
41 Cantoblanco, 28049, Madrid, Spain.

42 # LT-F and IG contributed equally to this work.

43 \* Corresponding author: Jaime Feliu, Hospital Universitario La Paz, Paseo de la Castellana 261,  
44 28046, Madrid, Spain. Phone: +34 912071138 , [jaimefeliu@hotmail.com](mailto:jaimefeliu@hotmail.com)



46 **ABSTRACT**

47 **Background:** Anal squamous cell carcinoma is a rare tumor. Chemo-radiotherapy yields a 50%  
48 3-year relapse-free survival rate in advanced anal cancer, so improved predictive markers and  
49 therapeutic options are needed.

50 **Methods:** High-throughput proteomics and whole-exome sequencing were performed in 46  
51 paraffin samples from anal squamous cell carcinoma patients. Hierarchical clustering was used  
52 to establish groups *de novo*. Then, probabilistic graphical models were used to study the  
53 differences between groups of patients at the biological process level.

54 **Results:** A molecular classification into two groups of patients was established, one group with  
55 increased expression of proteins related to adhesion, T lymphocytes and glycolysis; and the  
56 other group with increased expression of proteins related to translation and ribosomes. The  
57 probabilistic graphical model showed that these two groups presented differences in  
58 metabolism, mitochondria, translation, splicing and adhesion processes. Additionally, these  
59 groups showed different frequencies of genetic variants in some genes, such as *ATM*, *SLFN11*  
60 and *DST*. Finally, genetic and proteomic characteristics of these groups suggested the use of  
61 some possible targeted therapies, such as PARP inhibitors or immunotherapy.

62 **Conclusions:** In this study, a molecular classification of anal squamous cell carcinoma using  
63 high-throughput proteomics and whole-exome sequencing data was proposed. Moreover,  
64 differences between the two established groups suggested some possible therapies.

65 **Keywords:** anal squamous cell carcinoma, whole-exome sequencing, proteomics, molecular  
66 classification, personalized medicine.

67

## 68 **Background**

69 Anal squamous cell carcinoma (ASCC) is a relatively rare cancer. In the United States there are  
70 8,000 new estimated cases per year, accounting for approximately 2.7% of all gastrointestinal  
71 cancers. Of these, more than 1,000 cases will result in death(1).

72 Since the 1970s, the standard treatment has consisted of the combination of 5-fluorouracil  
73 (5FU), mitomycin C or cisplatin and radiotherapy (2). This treatment is particularly effective in  
74 T1/T2 tumors, achieving complete regression in 80-90% of cases. However, in advanced anal  
75 cancers (T3-4 or N+), the disease-free survival (DFS) rate is only around 50% (3). Therefore, due  
76 to the lack of advances in the last years, new therapeutic strategies are needed to improve  
77 these outcomes.

78 Whole-exome sequencing (WES) focused on the identification of disease-causing genes is now  
79 being implemented into clinical practice (4). The first work that announced entire exome  
80 sequencing was published by Ng et al (5). Since then, personalized medicine has focused on  
81 identifying the cause of rare diseases and cancers.

82 With the recent improvements in mass-spectrometry (MS) techniques, high-throughput  
83 proteomics has made it possible to identify thousands of proteins (6). Proteins are the  
84 effectors of biological processes, being closer to the phenotype than genes or transcripts. On  
85 the other hand, probabilistic graphical models (PGMs) were successfully used in previous  
86 studies to characterize tumors from a functional perspective (7-9). Moreover, when used in  
87 combination, proteomics and genomics provide complementary information.

88 Previous studies in ASCC were focused in the characterization of genetic variants in this disease  
89 using next-generation sequencing techniques. The most frequent mutated genes, such as  
90 *PIK3CA*, *FBXW7*, *FAT1* or *ATM*, were characterized (10-13). On the other hand, Herfs et al. used  
91 MS proteomics in microdissected anal samples to establish differential protein expression

92 patterns depending of the location (squamous or transitional) (14). However, until date, a  
93 molecular classification of ASCC has not been established

94 In this study, we combined WES with high-throughput proteomics to further characterize a  
95 cohort of 46 ASCC tumors. This is the first time that a combined study of these characteristics  
96 in ASCC has been done. Genomics provides information about the genetic causes of disease  
97 and proteins are the ultimate effectors of biological processes. Therefore, a study of these two  
98 –omics allows us to obtain a broader picture of the molecular features of ASCC tumors.

99

100 **Methods**

101 *Patient cohort*

102 Forty-six formalin-fixed, paraffin-embedded (FFPE) samples from patients diagnosed with ASCC  
103 were analyzed by WES and MS proteomics. The study was approved by the Ethical Committee  
104 of Hospital Universitario La Paz. Informed consent was obtained for all patients in the study.  
105 Samples were reviewed by an experienced pathologist and all the samples included at least  
106 70% invasive tumor cells. Patients were required to have a histologically-confirmed diagnosis  
107 of ASCC, be 18 years of age or older; have an Eastern Cooperative Oncology Group  
108 performance status (ECOG-PS) of 0 to 2; have received no prior radiotherapy or chemotherapy  
109 for this malignancy and present with no metastasis. Demographic information related to the  
110 tumor and the treatments was collected. Human papilloma virus (HPV) infection was  
111 determined by CLART® HPV2 (Genomica).

112 *DNA isolation*

113 One 10 mm section from each FFPE sample was deparaffinized and DNA was extracted using  
114 GeneRead DNA FFPE Kit (Qiagen), in accordance with the manufacturer's instructions. Once  
115 eluted, the DNA was frozen at -80 °C until use.

116 *Protein isolation*

117 Proteins were extracted from FFPE samples as previously described (15). Briefly, FFPE sections  
118 were deparaffinized in xylene and washed twice with absolute ethanol. Protein extracts were  
119 prepared in a 2% SDS buffer by a protocol based on heat-induced antigen retrieval. Protein  
120 concentration was measured using the MicroBCA Protein Assay Kit (Pierce-Thermo Scientific).  
121 Protein extracts (10 µg) were digested with trypsin (1:50) and SDS was removed from the  
122 digested lysates using Detergent Removal Spin Columns (Pierce). Peptides were desalted using

123 self-packed C18 stage tips, dried and resolubilized with 10 µl of 3% acetonitrile, 0.1% formic  
124 acid.

#### 125 *Whole-exome sequencing experiments*

126 WES from 46 ASCC FFPE samples was performed. The isolated DNA was evaluated by  
127 Picogreen and mean size was controlled by gel electrophoresis. Genomic DNA was divided by  
128 mechanical methods (Bioruptor) to a mean size of approximately 200 bp. At that point, DNA  
129 tests were fixed, phosphorylated, A-followed and ligated to explicit connectors, trailed by PCR-  
130 interceded naming with Illumina-explicit successions and test explicit standardized  
131 identifications (Kapa DNA library age unit).

132 Exome capture was performed utilizing the VCRome framework (catch size of 37 Mb,  
133 Nimblegen) under a multiplexing of 8 tests for every capture response. Capture was performed  
134 entirely in accordance to Nimblegen enhancement instructions. After the capture, libraries  
135 were cleansed, measured and titrated using Real Time PCR before sequencing. Tests were then  
136 sequenced to a surmised inclusion of 4.5 Gb per test in Illumina-NextSeq NS500 (Illumina Inc.)  
137 utilizing 150 cycles (2x75) High Output cartridges.

138 Raw data files were available in Sequence Read Archive (SRA,  
139 <https://www.ncbi.nlm.nih.gov/sra>) under the name PRJNA573670.

#### 140 *Bioinformatics analyses of whole-exome sequencing data*

141 The quality of the WES experiments was verified using FASTQC (<http://www.bioinformatics>.  
142 [babraham.ac.uk/projects/fastqc](http://babraham.ac.uk/projects/fastqc)). First, primers were removed using Cutadapt. Then, FASTQ  
143 files were filtered by quality using PrinSeq. Both tools are available in GPRO tool (16).  
144 Sequence alignment was performed using the human genome h19 as the reference and BWA  
145 tools (17), Samtools (18) and Picard Tools (<http://picard.sourceforge.net>). Variant calling was



146 performed using the MuTect tool from the GATK4 package (19) combined with PicardTools,  
147 first, to create a panel of normal samples (PON) and second, to perform the variant calling  
148 (20). The PON was built using 11 samples from Iberian exomes from a 1000genomes database  
149 (<http://www.ncbi.nlm.nih.gov/sra/>).

150 Finally, variants were annotated using Variant Effect Predictor (VEP) (21). The information  
151 about the genetic variants provided by VEP was used to filter the genetic variants. The filtering  
152 criteria were: a frequency in the general population, according gnomAD database, of less than  
153 1%, a high or moderate impact, and the presence of a variant of this gene in our cohort in at  
154 least 10% of the patients.

#### 155 *Liquid chromatography-mass spectrometry analysis*

156 MS analysis was performed using a Q Exactive HF-X mass spectrometer (Thermo Scientific)  
157 equipped with a Digital PicoView source (New Objective) and coupled to a M-Class UPLC  
158 (Waters). Solvent composition at the two channels was 0.1% formic acid for channel A and  
159 0.1% formic acid, 99.9% acetonitrile for channel B. For each sample 3  $\mu$ L of peptides were  
160 loaded on a commercial MZ Symmetry C18 Trap Column (100 $\text{\AA}$ , 5  $\mu$ m, 180  $\mu$ m x 20 mm,  
161 Waters) followed by nanoEase MZ C18 HSS T3 Column (100 $\text{\AA}$ , 1.8  $\mu$ m, 75  $\mu$ m x 250 mm,  
162 Waters). The peptides were eluted at a flow rate of 300 nL/min by a gradient from 8 to 27% B  
163 in 85 min, 35% B in 5 min and 80% B in 1 min. Samples were acquired in a randomized order.  
164 The mass spectrometer was operated in data-dependent acquisition mode (DDA), acquiring  
165 full-scan MS spectra (350–1'400 m/z) at a resolution of 120'000 at 200 m/z after accumulation  
166 to a target value of 3'000'000, followed by HCD (higher-energy collision dissociation)  
167 fragmentation on the twenty most intense signals per cycle. HCD spectra were acquired at a  
168 resolution of 15'000 using normalized collision energy of 28 and a maximum injection time of  
169 22 ms. The automatic gain control (AGC) was set to 100'000 ions. Charge state screening was  
170 enabled. Singly, unassigned, and charge states higher than seven were rejected. Only those

171 precursors with an intensity above 110'000 were selected for MS/MS. Precursor masses  
172 previously selected for MS/MS measurement were excluded from further selection for 30 s,  
173 and the exclusion window was set at 10 ppm. The samples were acquired using internal lock  
174 mass (22) calibration on m/z 371.1012 and 445.1200.

175 The MS proteomics results were handled using the local laboratory information management  
176 system (LIMS) (22) and all relevant data have been deposited to Chorus under the project  
177 name "Anal squamous cell carcinoma proteomics".

#### 178 *Protein identification and label-free protein quantification*

179 The acquired raw MS data was processed by MaxQuant (version 1.6.2.3), followed by protein  
180 identification using the integrated Andromeda search engine (23). Spectra were searched  
181 against a Uniprot reference proteome (taxonomy 9606, canonical version from 2016-12-09),  
182 concatenated to its reversed decoyed fasta database and common protein contaminants.  
183 Methionine oxidation and N-terminal protein acetylation were set as variable modifications.  
184 Enzyme specificity was set to trypsin/P allowing for a minimal peptide length of 7 amino acids  
185 and a maximum of two missed-cleavages. MaxQuant Orbitrap default search settings were  
186 used. The maximum false discovery rate (FDR) was set to 0.01 for peptides and 0.05 for  
187 proteins. Label-free quantification was enabled and a 2 minutes window for match between  
188 runs was applied. In the MaxQuant experimental design template, each file is kept separate in  
189 the experimental design to obtain individual quantitative values.

190 As quality criteria, the detectable measurement in at least 75% of the samples and the  
191 presence of two unique peptides were applied. Log<sub>2</sub> of the data was calculated and missing  
192 values were imputed to a normal distribution using Perseus software (24).

#### 193 *Probabilistic graphical models and functional node activity*

194 With the aim of studying proteomics data from a functional point of view, PGMs compatible  
195 with high-dimensional data, were used. *graphD* (25) and R v3.2.5 were used to generate the  
196 PGM from proteomics expression without any *a priori* information, based on correlation as  
197 associative measurement. The network was built in two steps: first, the spanning tree with  
198 maximum likelihood was found and, then, the edges was chosen based on the reduction of the  
199 Bayesian Information Criteria (BIC) and the preservation of the decomposability of the graph  
200 (26). The resulting network was analyzed to define a functional structure by gene ontology  
201 analyses, as in previous works (7-9). Briefly, the branches of the network were analyzed by  
202 gene ontology and a majority function for each branch was assigned, thereby determining  
203 different functional nodes in the network. Gene ontology analyses were performed using  
204 DAVID 6.8 webtool (27) using “homo sapiens” as background and GOTERM-FAT, Biocarta and  
205 KEGG as categories.

206 Once each branch had been assigned a function, functional node activities were calculated as  
207 the mean of the proteins of each branch related to the main function of that branch (8, 9).  
208 Then, comparisons between groups using Mann-Whitney test were done.

#### 209 *Metabolic modeling and estimation of tumor growth rate*

210 Flux Balance Analysis (FBA) is a method used to model the flow of metabolites through  
211 biochemical networks (28). It allows the growth rate or production rate of a given metabolite  
212 to be estimated using as input gene or protein expression data. In this study we used the  
213 whole human reconstruction Recon2 and the biomass reaction included in this model as the  
214 objective function and as representative of tumor growth (29). Proteomics data was  
215 introduced into the model to make accurate predictions by solving Gene-Protein-Reaction  
216 rules (GPRs), which contain the relationships between genes and enzymes, using a modified  
217 algorithm of Barker et al. (30) and a modified E-flux (7, 31). FBA calculations were performed  
218 using the COBRA Toolbox library, available for MATLAB (32).

219 *Statistical analyses*

220 Statistical analyses were performed in GraphPad Prism 6 and SPSS IBM Statistics 20. Network  
221 analyses were performed using Cytoscape software. Hierarchical cluster and Significance  
222 Analysis of Microarrays (SAM) were performed using MeV software. SAM analysis allows the  
223 identification of differential proteins between groups by a t-test corrected by permutations  
224 over the number of samples. The significance was determined using the False Discovery Rate  
225 (FDR) (33). The Genomics of Drug Sensitivity in Cancer database  
226 (<https://www.cancerrxgene.org/>) was used to find possible therapeutic targets. P-values are  
227 two-sided and considered statistically significant under 0.05.

228

229 **Results**

230 *Patient cohort*

231 Forty-six patients diagnosed with non-metastatic ASCC were recruited for this study. Twenty-  
232 eight patients came from the VITAL clinical trial (GEMCAD-09-02, NCT01285778), treated with  
233 panitumumab, 5FU, Mitomycin C, and radiotherapy. The other 18 patients were included from  
234 the routine clinical practice at Hospital Universitario La Paz and Hospital Clinic and were  
235 treated with cisplatin-5FU or Mitomycin C-5FU, and concomitant radiotherapy.

236 For the survival analyses, 4 patients that could not receive chemo-radiotherapy were excluded  
237 (two of them had stage I anal carcinomas, and the other two had stage III tumors). The median  
238 follow-up was 33.18 months (5.53-116.4) and there are 13 relapse events. All clinical  
239 characteristics are shown in Table 1.

240 *Whole-exome sequencing experiments*

241 Forty-six FFPE samples were analyzed by WES. The mean coverage of the samples was 42.6x,  
242 with the exception of one sample that presented a coverage of 3.57x. This sample was  
243 dismissed from the subsequent analyses. Once this sample was dismissed, all the samples  
244 presented a mapping efficiency of 90-98%, with the exception of one sample (with a mapping  
245 efficiency of 75.4%). Human exome has > 195,238 exonic regions, of which only 23,021  
246 (11.21% of the human exome) have not been mapped in any sample.

247 After VEP analysis and filtering, 382 genes that presented a genetic variant with high or  
248 moderate impact in at least 10% of our cohort were identified (Sup Table 1). These genes were  
249 mostly related to DNA repair, chromatin binding and focal adhesion processes. *PIK3CA* was  
250 mutated in the 40% of the patients of our cohort, *FBXW7* in 16%, *FAT1* in 18%, and *ATM* was  
251 mutated in 27% of the patients. Figure 1 summarizes the high and moderate impact alteration  
252 landscape in ASCC.

253 *Proteomics experiments*

254 After dismissing one sample in the WES experiments, 45 FFPE samples were analyzed by MS  
255 and 6,035 proteins were identified. After applying quality criteria (detectable measurement in  
256 at least 75% of the samples and at least two unique peptides), 1,954 proteins were used for  
257 the subsequent analyses.

258 *De novo identification of groups based on differential proteomics profiles*

259 With the aim of defining *de novo* molecular groups of patients, a hierarchical cluster was used.  
260 Two different molecular groups were obtained. A SAM was performed to define the  
261 differential proteins between these two groups, yielding 318 proteins which were differentially  
262 expressed between these groups (Sup Table 2). Group 1 underexpressed proteins related to  
263 translation and ribosomal processes and overexpressed proteins related to metabolism,  
264 specially glycolysis, T lymphocytes, and adhesion. On the other hand, Group 2 underexpressed  
265 proteins related to metabolism, T lymphocytes, and adhesion processes and overexpressed  
266 proteins related to translation and ribosomes (Figure 2).

267 With respect to the clinical data distribution between these two groups, both were  
268 comparable; there were no significant differences in the distribution of clinical parameters  
269 (Sup Table 3). In addition, there were not significant differences in disease-free survival or  
270 overall survival (Sup Fig 1).

271 A search in the Genomics of Drug Sensitivity in Cancer database  
272 (<https://www.cancerrxgene.org/>) suggested RAC1 (overexpressed in Group1 and  
273 underexpressed in Group 2) as a possible therapeutic target. The drug associated with this  
274 gene is EHT-1864.

275 *Functional characterization of proteomics data*

276 To study proteomics data from a functional perspective, a PGM was created using the 1,954  
277 proteins obtained from the MS experiments. The resulting network was divided into 10  
278 functional nodes, one of them with an overrepresentation of two biological functions  
279 (metabolism and mitochondria) (Figure 3).

280 Then, functional node activities were used, as in previous works (7-9), to study the differences  
281 in biological processes between the two identified groups of patients. There were significant  
282 differences between the two groups in membrane category, in the two nodes related to  
283 metabolism, and in the nodes associated with adhesion, ribosomes, translation, extracellular  
284 matrix and splicing (Figure 4).

#### 285 *Metabolism nodes*

286 We found two different nodes related to metabolism, both of which showed a higher  
287 expression in Group 1. The metabolism 1 node was formed by 158 proteins, mostly related to  
288 mitochondrial metabolism, especially the tricarboxylic acid cycle. Among them, three were  
289 also identified as differentially expressed by the SAM analysis: P09622 (DLD), P06744 (GPI) and  
290 P14550 (AKR1A1). The metabolism 2 node included 104 proteins related to mitochondria and  
291 metabolism, especially oxidative phosphorylation, such as P04406 (GAPDH), P06733 (ENO1),  
292 P07954 (FH) or Q9UI09 (NDUFA12).

#### 293 *Adhesion node*

294 The adhesion node showed a higher expression in Group 1. The adhesion node included 654  
295 proteins, 25 of them classified by SAM as differentially expressed between the two groups of  
296 patients.

297 *Genetic variants with different frequencies between the two groups of patients established by*  
298 *proteomics*

299 Using a Chi-squared test, the frequencies of genetic variants for each gene were compared to  
300 determine whether the groups of patients defined using proteomics data also showed  
301 differences in genetic variants. Twelve genes presented different frequencies of genetic  
302 variants between the two groups (Figure 5).

303 *Tumor growth rate predicted by metabolic modeling*

304 FBA allows for the comparison of the tumor growth rate between groups of tumors. The tumor  
305 growth rate predicted for Group 1 was significantly higher than the tumor growth rate  
306 predicted for Group 2 (Figure 6).

307



308 **Discussion**

309 ASCC is an infrequent tumor. With no targeted therapy yet established, the molecular  
310 characterization of these tumors is still necessary. In this study, we combined the two main –  
311 omics, WES and proteomics, to further characterize a cohort of 46 patients diagnosed with  
312 primary ASCC. To our knowledge, this is the first study combining WES and proteomics in  
313 ASCC. The results of this study allow us to establish two molecular subgroups in ASCC with  
314 different molecular features. Moreover, the analyses of these two groups pointed out some  
315 drug-susceptible processes, such as metabolism, and suggested other possible therapeutic  
316 targets, like *ATM* and its relationship with PARP inhibitors (PARPi).

317 Previous studies have analyzed both primary and metastatic ASCC paraffin samples using WES  
318 or gene panels (10-13). A previous study using proteomics data to characterize different  
319 locations of anal cancer was also existed (14). However, this is the first study that performs  
320 proteomics experiments in localized ASCC samples and combines proteomics data with WES  
321 information. Previous WES studies served to identify frequently-occurring mutations in this  
322 disease, including mutations in the *PIK3CA*, *FBXW7*, *FAT1* and *ATM* genes (11-13). In our  
323 cohort, *PIK3CA* presented a genetic variant with a high or modifier impact in 40% of the  
324 patients, *FBXW7* in 16%, *FAT1* in 18%, and *ATM* in 27% of the patients.

325 Using proteomics data and HCL, it was possible to establish two different molecular groups of  
326 patients. Differential proteins were mainly related to the metabolism of glucose, translation  
327 and ribosomes, T lymphocytes and adhesion. Although these molecular groups have not been  
328 associated with any clinical or prognostic features, these processes may be relevant in the  
329 development of new therapeutic strategies. For instance, those tumors that overexpressed  
330 proteins related to glycolysis may be candidates for drugs targeting metabolism such as  
331 metformin, which has been shown to have cytostatic effects on other tumors, such as breast  
332 or bladder carcinoma (7). On the other hand, one of the main differences between these two

333 groups is that Group 1 had a higher expression of proteins related to T lymphocytes. With the  
334 bloom of immunotherapies, immune proteins have acquired great relevance. Therefore, this  
335 group of patients may be good candidates for immunotherapy. In fact, nivolumab has been  
336 reported to be an effective therapy in metastatic ASCC and its efficacy is related to the  
337 presence of cytotoxic T cells (34). Moreover, pembrolizumab has demonstrated its antitumor  
338 activity in PD-L1-positive advanced ASCC (35). On the other hand, the search in Genomics of  
339 Drug Sensitivity in Cancer database to establish possible therapeutic targets suggested RAC1  
340 (overexpressed in Group 1 and underexpressed in Group 2) as a potential therapeutic target.  
341 RAC1 has as associated drug, EHT-1864, which affects the cytoskeleton (36).

342 In addition, MS experiments and PGMs allow for the functional characterization of these two  
343 groups of patients. In this functional analysis, differences in metabolism were confirmed.  
344 There were also differences at the mitochondria level, which is the target for metformin.  
345 Metabolism nodes showed a higher expression in Group 1. P06744 (GPI, glucose 6-phosphate  
346 isomerase), included in the metabolism 1 node, is the enzyme that converts glucose –  
347 phosphate into fructose 6-phosphate and a higher expression has been associated with  
348 tumorigenesis and poor prognosis in gastric cancer (37).

349 The adhesion node also had a higher expression in Group 1 and contained 25 proteins  
350 identified by SAM as differentially expressed. P46940 (IQGAP1) has been associated with poor  
351 prognosis in head and neck squamous cell carcinoma (38) and has also been associated with  
352 response to chemo-radiotherapy in rectal adenocarcinomas (39). P27797 (CALR) induces an  
353 immune response in esophageal squamous cell carcinoma (40). P08133 (ANXA6) promotes  
354 EGFR deactivation (41). P62829 (RPL23) negatively regulates apoptosis and also inhibits growth  
355 in colorectal cancer (42). On the other hand, RPL23 has been identified as an oncogene in head  
356 and neck squamous cell carcinoma (43). O43707 (ACTN4) increases cell motility and invasion in  
357 colorectal cancer (44). Previous studies have described how P84077 (ARF1) forms a complex

358 with EGFR and promotes invasion in head and neck squamous cell carcinoma (45). P35579  
359 (MYH9) plays an important role in adhesion and migration, and its overexpression is correlated  
360 with metastasis in colorectal cancer through the MAPK pathway (46) . Aberrant activity of  
361 P63000 (RAC1), which is involved in metastasis and proliferation, is a hallmark in cancer, (47).  
362 At the same time, O75131 (CPNE3) promotes cell migration through RAC1 (48). Finally, P61586  
363 (RHOA), a tumor suppressor gene, plays a relevant role in colorectal cancer, being associated  
364 with metastasis and is deactivated in a significant number of colorectal tumors (49).In  
365 conclusion, the majority of the proteins included in this adhesion node play well-established  
366 roles in metastasis processes.

367 Moreover, the combination of the proteomics and genetic variants information showed that  
368 the two molecular groups defined by proteomics also had a different mutational profile. Group  
369 2 showed a higher frequency of *ATM* genetic variants. Previous studies have described a high  
370 response rate to PARPi, as olaparib, in prostate tumors with mutations in *ATM* (50). Therefore,  
371 Group 2 patients may also be candidates for the treatment with PARPi.

372 In addition, FBA predicted a higher tumor growth rate for Group 1 than for Group 2. It may be  
373 possible that, given their higher proliferation, the tumors of Group 1 may also be more  
374 responsive to chemotherapy.

375 This study has some limitations. The results need to be validated in an independent cohort.  
376 The information in ASCC is scarce so a prospective validation will be needed. The number of  
377 proteins detected by MS still needs technical improvement to be considered to be at the same  
378 level as genomics. However, proteomics offers a more direct measurement of the effectors of  
379 biological processes. Finally, a consensus analysis pipeline to apply in cancer sequencing data is  
380 still necessary.

## 381 **Conclusions**

382 In conclusion, two different molecular groups of patients have been proposed based on  
383 proteomics expression. This may be the first step toward a personalized therapy approach in  
384 ASCC. In addition, some possible targeted therapies, such as PARPi or immunotherapy,  
385 according to the molecular features (genetic and protein-based) defined in the two proteomics  
386 groups were suggested.

387 **List of abbreviations**

388 ASCC: Anal squamous cell carcinoma

389 5FU: 5-fluorouracil

390 DFS: disease-free survival

391 WES: whole-exome sequencing

392 MS: mass-spectrometry

393 PGM: probabilistic graphical model

394 FFPE: formalin-fixed paraffin-embedded

395 ECOG-PS: Eastern Cooperative Oncology Group performance status

396 HPV: Human papilloma virus

397 VEP: Variant Effect Predictor

398 DDA: Data-dependent acquisition

399 FDR: False Discovery Rate

400 FBA: Flux Balance Analysis

401 BIC: Bayesian Information Criterion

402 GPR: Gene-Protein-Reaction rules

403 SAM: Significance Analysis of Microarrays

404 PARPi: PARP inhibitors

405 **DECLARATIONS**

406 **Ethics approval and consent to participate:** This study was approved by the Ethics Committee  
407 of Hospital Universitario La Paz (PI-1926). Informed consents were obtained for all patients  
408 included in this study.

409 **Consent for publication:** Not applicable.

410 **Availability of data and material:** The proteomics data generated during the current study are  
411 available in Chorus repository (<https://chorusproject.org/pages/index.html>). The exome  
412 sequencing data are available in SRA (<https://www.ncbi.nlm.nih.gov/sra>) under the name  
413 PRJNA573670.

414 **Competing interests:** JAFV and AG-P are shareholders in Biomedica Molecular Medicine SL. LT-  
415 F and GP-V are employees of Biomedica Molecular Medicine SL. JC has received honoraria for  
416 scientific consulting (as speaker and advisory roles) from Novartis, Pfizer, Ipsen, Exelixis, Bayer,  
417 Eisai, Advanced Accelerator Applications, Amgen, Sanofi and Merck Serono and research  
418 support from Eisai, Novartis, Ipsen, Astrazeneca, Pfizer and Advanced Accelerator Applications.  
419 IG has received honoraria and/or travel expenses from Roche, Sanofi, Merck, Servier, Amgen  
420 and Sirtflex, and for advisory role from Merck and Sanofi. JF has received consulting and  
421 advisory honoraria from Amgen, Ipsen, Eisai, Merck, Roche and Novartis; research funding  
422 from Merck, and travel and accommodation expenses from Amgen and Servier. The other  
423 authors declare no conflicts of interest.

424 **Funding:** This study was supported by the Instituto de Salud Carlos III, Spanish Economy and  
425 Competitiveness Ministry, Spain and co-sponsored by the FEDER program, “Una forma de  
426 hacer Europa” (PI15/01310), a Roche Farma grant, Cátedra UAM-Amgen and a grant of Grupo  
427 Español Multidisciplinar en Cáncer Digestivo (GEMCAD1403). LT-F is supported by the Spanish  
428 Economy and Competitiveness Ministry (DI-15-07614). GP-V is supported by the Consejería de  
429 Educación, Juventud y Deporte of Comunidad de Madrid (IND2017/BMD7783); AZ-M is  
430 supported by Jesús Antolín Garcíarena fellowship from IdiPAZ. The sponsors were not involved  
431 in the study design, in data collection and analysis, in the decision to publish or in the  
432 preparation of this manuscript.

433 **Authors’ contributions:** All the authors have directly participated in the preparation of this  
434 manuscript and have approved the final version submitted and declare no ethical conflicts of  
435 interest. RL-V, MM, EL-C, and VH contributed the DNA and protein extraction. MM and VH  
436 contributed the HPV determination. LG-P, CP, and MC contributed the pathological review of  
437 the samples. PN and CF contributed the mass spectrometry data. RR-R and CL contributed the  
438 sequencing analyses. LT-F, AG-P and JAFV contributed the probabilistic graphical models. LT-F  
439 contributed the FBA analyses. IG, JM, PG-A, JC, CC, RG-C, and JF contributed the clinical data  
440 and the analyses related. LT-F, IG, AG-P, GP-V, and AZ-M contributed in the design of the study  
441 and the statistical and gene ontology analyses. L-T-F drafted the manuscript. IG, JM, JAFV, and  
442 JF conceived of the study, and participated in its design and interpretation. AG-P, JM, JAFV,  
443 and JF reviewed the manuscript. JF coordinated the study. All authors read and approved the  
444 final manuscript.

445

446

447

448

449

450 **REFERENCES**

451 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin.* 2018;68(1):7-30.

452 2. Benson A, Venook A, Al-Hawary M, Cederquist L, Chen Y, Ciombor K, et al. Anal  
453 carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc*  
454 *Netw.* 2018. p. 852-71.

455 3. Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB, et al. Long-  
456 term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival,  
457 relapse, and colostomy failure with concurrent chemoradiation involving  
458 fluorouracil/mitomycin versus fluorouracil/cisplatin. *J Clin Oncol.* 2012;30(35):4344-51.

459 4. Tetreault M, Bareke E, Nadaf J, Alirezaie N, Majewski J. Whole-exome sequencing as a  
460 diagnostic tool: current challenges and future opportunities. *Expert Rev Mol Diagn.*  
461 2015;15(6):749-60.

462 5. Ng S, Turner E, Robertson P, Flygare S, Bigham A, Lee C, et al. Targeted capture and  
463 massively parallel sequencing of 12 human exomes. *Nature.* 2009;461 (7261):272-6.

464 6. Meier F, Geyer PE, Virreira Winter S, Cox J, Mann M. BoxCar acquisition method  
465 enables single-shot proteomics at a depth of 10,000 proteins in 100 minutes. *Nat Methods.*  
466 2018.

467 7. Trilla-Fuertes L, Gámez-Pozo A, Arevalillo JM, Díaz-Almirón M, Prado-Vázquez G,  
468 Zapater-Moros A, et al. Molecular characterization of breast cancer cell response to metabolic  
469 drugs. *Oncotarget.* 2018;9(11):9645-60.

470 8. Gámez-Pozo A, Trilla-Fuertes L, Berges-Soria J, Selevsek N, López-Vacas R, Díaz-Almirón  
471 M, et al. Functional proteomics outlines the complexity of breast cancer molecular subtypes.  
472 *Scientific Reports.* 2017;7(1):10100.

- 473 9. Gámez-Pozo A, Berges-Soria J, Arevalillo JM, Nanni P, López-Vacas R, Navarro H, et al.  
474 Combined label-free quantitative proteomics and microRNA expression analysis of breast  
475 cancer unravel molecular differences with clinical implications. *Cancer Res*; 2015. p. 2243-53.
- 476 10. Cacheux W, Rouleau E, Briaux A, Tsantoulis P, Mariani P, Richard-Molard M, et al.  
477 Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with  
478 poor outcome after salvage abdominoperineal resection. *Br J Cancer*. 2016;114(12):1387-94.
- 479 11. Cacheux W, Dangles-Marie V, Rouleau E, Lazartigues J, Girard E, Briaux A, et al. Exome  
480 sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal  
481 squamous cell carcinoma. *Oncotarget*. 2018;9(1):464-76.
- 482 12. Morris V, Rao X, Pickering C, Foo WC, Rashid A, Eterovic K, et al. Comprehensive  
483 Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. *Mol Cancer Res*.  
484 2017;15(11):1542-50.
- 485 13. Chung JH, Sanford E, Johnson A, Klempner SJ, Schrock AB, Palma NA, et al.  
486 Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically  
487 defined classes. *Ann Oncol*. 2016;27(7):1336-41.
- 488 14. Herfs M, Longuespée R, Quick CM, Roncarati P, Suarez-Carmona M, Hubert P, et al.  
489 Proteomic signatures reveal a dualistic and clinically relevant classification of anal canal  
490 carcinoma. *J Pathol*. 2017;241(4):522-33.
- 491 15. Gámez-Pozo A, Ferrer NI, Ciruelos E, López-Vacas R, Martínez FG, Espinosa E, et al.  
492 Shotgun proteomics of archival triple-negative breast cancer samples. *Proteomics Clin Appl*.  
493 2013;7(3-4):283-91.
- 494 16. Futami R, Muñoz-Pomer A, Viu J, Domínguez-Escribá R, Covelli L, Bernet G, et al. GPRO  
495 The professional tool for annotation, management and functional analysis of omic databases.  
496 *Biotechvana Bioinformatics: SOFT3*. 2011.
- 497 17. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler  
498 transform. *Bioinformatics*. 2009;25(14):1754-60.



- 499 18. Li H, Handsaker B, Wysoker B, Fennell T, Ruan J, Homer N, et al. The Sequence  
500 Alignment/Map format and SAMtools. *Bioinformatics*. 2009;25:2078-9.
- 501 19. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytzsky A, et al. The  
502 Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA  
503 sequencing data. *Genome Research*. 2010;20(9):1297-303.
- 504 20. Cibulskis K, Lawrence M, Carter S, Sivachenco A, Jaffe D, Sougnez C, et al. Sensitive  
505 detection of somatic point mutations in impure and heterogeneous cancer samples. *Nature*  
506 *Biotechnology*. 2013;31(3):213-9.
- 507 21. Cunningham F, Amode MR, Barrell D, Beal K, Billis K, Brent S, et al. Ensembl 2015.  
508 *Nucleic Acids Res*. 2015;43(Database issue):D662-9.
- 509 22. Turker CA, F, Joho D, Panse B, Oesterreicher B, Rehrauer H, Schlapbach R. B-Fabric: The  
510 Swiss Army Knife for Life Sciences. Lausanne, Switzerland EDBT; 2010.
- 511 23. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized  
512 p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol*.  
513 2008;26(12):1367-72.
- 514 24. Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The Perseus  
515 computational platform for comprehensive analysis of (prote)omics data. *Nat Methods*.  
516 2016;13(9):731-40.
- 517 25. Abreu G, Edwards D, Labouriau R. High-Dimensional Graphical Model Search with  
518 the gRapHD R Package *Journal of Statistical Software* 2010. p. 1-18.
- 519 26. Lauritzen S. *Graphical Models*. Oxford, UK.: Oxford University Press 1996.
- 520 27. Huang dW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene  
521 lists using DAVID bioinformatics resources. *Nat Protoc*. 2009;4(1):44-57.
- 522 28. Orth J, Thiele I, Palsson B. What is flux balance analysis? : *Nat Biotechnol*; 2010. p. 245-  
523 8.

- 524 29. Thiele I, Swainston N, Fleming RM, Hoppe A, Sahoo S, Aurich MK, et al. A community-  
525 driven global reconstruction of human metabolism. *Nat Biotechnol.* 2013;31(5):419-25.
- 526 30. Barker BE, Sadagopan N, Wang Y, Smallbone K, Myers CR, Xi H, et al. A robust and  
527 efficient method for estimating enzyme complex abundance and metabolic flux from  
528 expression data. *Comput Biol Chem.* 2015;59 Pt B:98-112.
- 529 31. Colijn C, Brandes A, Zucker J, Lun D, Weiner B, Farhat M, et al. Interpreting expression  
530 data with metabolic flux models: Predicting *Mycobacterium tuberculosis* mycolic acid  
531 production. *PLOS Comput Bio*; 2009.
- 532 32. Schellenberger J, Que R, Fleming R, Thiele I, Orth J, Feist A, et al. Quantitative  
533 prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0.  
534 *Nature Protocols*; 2011. p. 1290-307.
- 535 33. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the  
536 ionizing radiation response. *Proc Natl Acad Sci U S A.* 2001;98(9):5116-21.
- 537 34. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, et al. Nivolumab for  
538 previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm,  
539 phase 2 study. *Lancet Oncol.* 2017;18(4):446-53.
- 540 35. Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, et al.  
541 Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with  
542 recurrent carcinoma of the anal canal. *Ann Oncol.* 2017;28(5):1036-41.
- 543 36. Onesto C, Shutes A, Picard V, Schweighoffer F, Der CJ. Characterization of EHT 1864, a  
544 novel small molecule inhibitor of Rac family small GTPases. *Methods Enzymol.* 2008;439:111-  
545 29.
- 546 37. Ma YT, Xing XF, Dong B, Cheng XJ, Guo T, Du H, et al. Higher autocrine motility  
547 factor/glucose-6-phosphate isomerase expression is associated with tumorigenesis and poorer  
548 prognosis in gastric cancer. *Cancer Manag Res.* 2018;10:4969-80.

- 549 38. Wu CC, Li H, Xiao Y, Yang LL, Chen L, Deng WW, et al. Over-expression of IQGAP1  
550 indicates poor prognosis in head and neck squamous cell carcinoma. *J Mol Histol.*  
551 2018;49(4):389-98.
- 552 39. Holck S, Nielsen HJ, Hammer E, Christensen IJ, Larsson LI. IQGAP1 in rectal  
553 adenocarcinomas: localization and protein expression before and after radiochemotherapy.  
554 *Cancer Lett.* 2015;356(2 Pt B):556-60.
- 555 40. Liu X, Song N, Liu Y, Li J, Ding J, Tong Z. Efficient induction of anti-tumor immune  
556 response in esophageal squamous cell carcinoma via dendritic cells expressing MAGE-A3 and  
557 CALR antigens. *Cell Immunol.* 2015;295(2):77-82.
- 558 41. Koese M, Rentero C, Kota BP, Hoque M, Cairns R, Wood P, et al. Annexin A6 is a  
559 scaffold for PKC $\alpha$  to promote EGFR inactivation. *Oncogene.* 2013;32(23):2858-72.
- 560 42. Qi Y, Li X, Chang C, Xu F, He Q, Zhao Y, et al. Ribosomal protein L23 negatively regulates  
561 cellular apoptosis via the RPL23/Miz-1/c-Myc circuit in higher-risk myelodysplastic syndrome.  
562 *Sci Rep.* 2017;7(1):2323.
- 563 43. Russo N, Wang X, Liu M, Banerjee R, Goto M, Scanlon C, et al. A novel approach to  
564 biomarker discovery in head and neck cancer using an autoantibody signature. *Oncogene.*  
565 2013;32(42):5026-37.
- 566 44. Honda K, Yamada T, Hayashida Y, Idogawa M, Sato S, Hasegawa F, et al. Actinin-4  
567 increases cell motility and promotes lymph node metastasis of colorectal cancer.  
568 *Gastroenterology.* 2005;128(1):51-62.
- 569 45. He L, Gao L, Shay C, Lang L, Lv F, Teng Y. Histone deacetylase inhibitors suppress  
570 aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent  
571 blockade of the EGFR-Arf1 axis. *J Exp Clin Cancer Res.* 2019;38(1):84.
- 572 46. Wang B, Qi X, Liu J, Zhou R, Lin C, Shangguan J, et al. MYH9 Promotes Growth and  
573 Metastasis via Activation of MAPK/AKT Signaling in Colorectal Cancer. *J Cancer.*  
574 2019;10(4):874-84.

- 575 47. Kazanietz MG, Caloca MJ. The Rac GTPase in Cancer: From Old Concepts to New  
576 Paradigms. *Cancer Res.* 2017;77(20):5445-51.
- 577 48. Ahmat Amin MKB, Shimizu A, Zankov DP, Sato A, Kurita S, Ito M, et al. Epithelial  
578 membrane protein 1 promotes tumor metastasis by enhancing cell migration via copine-III and  
579 Rac1. *Oncogene.* 2018;37(40):5416-34.
- 580 49. Dopeso H, Rodrigues P, Bilic J, Bazzocco S, Cartón-García F, Macaya I, et al.  
581 Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer. *Br J*  
582 *Cancer.* 2018;118(1):106-16.
- 583 50. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-Repair  
584 Defects and Olaparib in Metastatic Prostate Cancer. *N Engl J Med.* 2015;373(18):1697-708.

585

586

## 587 **TABLE AND FIGURE LEGENDS**

588 Figure 1: High and moderate impact genetic variants located in genes mutated in at least 20%  
589 of the ASCC patients of this cohort.

590 Figure 2: Significance Analysis of Microarrays identified 318 differential proteins between two  
591 groups of ASCC patients. Green=underexpressed. Red= overexpressed. In green, Group 1. In  
592 blue, Group 2.

593 Figure 3: Functional network created using the proteomics data from the ASCC patients. Ten  
594 nodes with different biological functions were identified.

595 Figure 4: Functional node activities between the two groups defined by the hierarchical  
596 cluster. \*\*\*\*:  $p < 0.0001$ ; \*\*\*:  $0.0001 \geq p \leq 0.001$ ; \*\*:  $0.01 \geq p \leq 0.05$ . G1= Group 1; G2= Group 2.

597 Figure 5: Genes with different frequency of genetic variants between the two groups of  
598 patients identified in proteomics. The mutation rate was calculated as the total number of  
599 mutations of a gene in each group divided by the number of patients assigned to that group.

600 Figure 6: Tumor growth rate predicted using metabolic models. a.u. = arbitrary units. \*: p  
601 <0.05

602 Sup Fig 1: A. Disease-free survival curves for the two groups defined by proteomics. B. Overall  
603 survival curves for the two groups defined by proteomics.













604 Table 1: Patient characteristics.

605 Sup Table 1: Genes with a detected genetic variant in at least 10% of the patients.

606 Sup Table 2: 318 differential proteins obtained by SAM between the two groups.

607 Sup Table 3: Clinical data distribution between the two molecular groups. p= p-values obtained  
608 from a Chi-squared test comparing the two groups of patients.

609






-4.0 0.0 4.0



G2  
G1



-1.284224

-0.642112

-0.0





ria & Metabolism

r matrix

